Skip to Main content Skip to Navigation
Journal articles

PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study

Abstract : PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy. We assessed the safety and immunogenicity of PRIMVAC adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) in French and Burkinabe women who were not pregnant.
Complete list of metadata

https://hal.inria.fr/hal-03161802
Contributor : Laura Richert <>
Submitted on : Wednesday, December 2, 2020 - 10:12:16 AM
Last modification on : Thursday, April 15, 2021 - 3:08:19 PM
Long-term archiving on: : Wednesday, March 3, 2021 - 6:26:53 PM

File

THELANCETID-HAL version.pdf
Files produced by the author(s)

Identifiers

Citation

Sodiomon Sirima, Laura Richert, Arnaud Chêne, Amadou Konate, Cécilia Campion, et al.. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2020, 20 (5), pp.585-597. ⟨10.1016/S1473-3099(19)30739-X⟩. ⟨hal-03161802v2⟩

Share

Metrics

Record views

166

Files downloads

492